Albert R Collinson

Title: Albert R. Collinson: Innovator in Blocked Lectins

Introduction

Albert R. Collinson is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of methods and materials related to lectins. His innovative work has led to the creation of a patent that addresses critical challenges in cell targeting and treatment.

Latest Patents

Collinson holds a patent for "Blocked lectins, methods and affinity support for making same using." This patent describes an activated affinity ligand that comprises a ligand with a region that binds to lectin binding sites and a reactive group that covalently links the ligand to the lectin. The invention includes a blocked lectin formed by covalently linking one or more affinity ligands to a lectin, effectively blocking its binding sites. Additionally, it details a cell-binding agent-blocked lectin conjugate and methods for preparing both the blocked lectin and the conjugate. The patent also outlines methods for targeting specific cell populations while minimizing cytotoxicity to non-selected cells, showcasing its potential in therapeutic applications.

Career Highlights

Collinson is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance research in cancer treatment and biochemistry. His work is instrumental in developing innovative solutions that enhance the efficacy of cancer therapies.

Collaborations

He has collaborated with notable colleagues, including John M. Lambert and Victor S. Goldmacher, contributing to a rich environment of innovation and research.

Conclusion

Albert R. Collinson's contributions to the field of biochemistry, particularly through his patent on blocked lectins, highlight his role as a key innovator in cancer research. His work not only advances scientific understanding but also paves the way for new therapeutic strategies.